GlassScriptPhysician profile
George Ahad
NPI 1932421559
$2,607.75
in general payments reported to CMS, 2019-2025
37 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $314 · 2021: $539 · 2022: $382 · 2023: $411 · 2024: $355 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.34 | 2019-2022 | |
| Hologic Sales and Service, LLC | $247.75 | 2022-2025 | Omni Hysteroscope, Aptima, Novasure |
| Myovant Sciences INC. | $132.71 | 2021-2022 | |
| Aspira Women'S Health INC | $128.87 | 2019-2024 | Ova1 |
| Pfizer INC. | $122.60 | 2022-2025 | |
| Biom'Up France Sas | $115.78 | 2020-2021 | |
| Organon LLC | $113.85 | 2022-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $112.60 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $108.33 | 2021-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Evofem Biosciences, INC. | $100.05 | 2021-2025 | Solosec, Phexx, Phexxi |
| Davol INC. | $62.26 | 2020 | |
| Baxter Healthcare | $60.24 | 2025 | Perclot |
| Glaxosmithkline, LLC. | $58.71 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $49.55 | 2021-2023 | Lyumjev, Baqsimi |
| Daiichi Sankyo INC. | $47.03 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $46.35 | 2024-2025 | Dexcom G6 Transmitter |
| Linus Health, INC. | $44.38 | 2023 | |
| Novo Nordisk INC | $42.30 | 2023-2025 | Rybelsus |
| Cranial Technologies, INC | $35.64 | 2024-2025 | Doc Band |
| Abbott Laboratories | $29.03 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $27.85 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $26.85 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $26.04 | 2021-2023 | Kristalose |
| Mayne Pharma Commercial LLC | $25.16 | 2025 | |
| Exeltis, USA INC. | $24.96 | 2025 | Slynd |
| Therapeuticsmd, INC. | $23.69 | 2021 | |
| Amag Pharmaceuticals, INC. | $23.37 | 2019 | |
| Applied Medical Resources Corporation | $22.92 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.31 | 2023 | Gvoke Hypopen |
| Agile Therapeutics, INC. | $19.21 | 2022 | |
| Ethicon US, LLC | $19.04 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.93 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.76 | 2024 | Voquezna |
| Minerva Surgical, INC | $15.50 | 2019 | |
| Amgen INC. | $13.46 | 2019 | |
| Allergan, INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Ahad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.